Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

The molecular basis of JAK/STAT inhibition by SOCS1

Open access

Abstract

The SOCS family of proteins are negative-feedback inhibitors of signalling induced by cytokines that act via the JAK/STAT pathway. SOCS proteins can act as ubiquitin ligases by recruiting Cullin5 to ubiquitinate signalling components; however, SOCS1, the most potent member of the family, can also inhibit JAK directly. Here we determine the structural basis of both these modes of inhibition. Due to alterations within the SOCS box domain, SOCS1 has a compromised ability to recruit Cullin5; however, it is a direct, potent and selective inhibitor of JAK catalytic activity. The kinase inhibitory region of SOCS1 targets the substrate binding groove of JAK with high specificity and thereby blocks any subsequent phosphorylation. SOCS1 is a potent inhibitor of the interferon gamma (IFNγ) pathway, however, it does not bind the IFNγ receptor, making its mode-of-action distinct from SOCS3. These findings reveal the mechanism used by SOCS1 to inhibit signalling by inflammatory cytokines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-04013-1

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 SOCS1 is a direct inhibitor of JAK kinase activity. a Schematic representation of the SOCS1 domain architecture. SOCS1 consists of an unstructured N-terminal region, followed by the kinase inhibitory region (KIR), an extended SH2 subdomain (ESS), a SH2 domain and a SOCS box domain. b Purified recombinant SOCS1 in complex with Elongins B and C shown on Coomassie stained SDS-PAGE gel. c Gel filtration analysis of purified recombinant SOCS1 in complex with Elongins B and C. d Kinase inhibition assays indicate that SOCS1 from Homo sapiens (hs), Gallus gallus (gg) and Xenopus laevis (xl) inhibits the kinase domains of JAK1, JAK2 and TYK2, but not JAK3. e IC50 values of SOCS1 and SOCS3 constructs against JAKs as determined by kinase inhibition assays. The error bars shown in d represent the range of the data from two technical replicates whilst errors given in e are the standard error of the mean from 3 independent experiments
Fig. 1 SOCS1 is a direct inhibitor of JAK kinase activity. a Schematic representation of the SOCS1 domain architecture. SOCS1 consists of an unstructured N-terminal region, followed by the kinase inhibitory region (KIR), an extended SH2 subdomain (ESS), a SH2 domain and a SOCS box domain. b Purified recombinant SOCS1 in complex with Elongins B and C shown on Coomassie stained SDS-PAGE gel. c Gel filtration analysis of purified recombinant SOCS1 in complex with Elongins B and C. d Kinase inhibition assays indicate that SOCS1 from Homo sapiens (hs), Gallus gallus (gg) and Xenopus laevis (xl) inhibits the kinase domains of JAK1, JAK2 and TYK2, but not JAK3. e IC50 values of SOCS1 and SOCS3 constructs against JAKs as determined by kinase inhibition assays. The error bars shown in d represent the range of the data from two technical replicates whilst errors given in e are the standard error of the mean from 3 independent experimentsCC BY · PubMed Central
Fig. 2 The structure of a SOCS1/JAK1/ADP complex. a Cartoon representation of the JAK1 (beige) /SOCS1 (red) /ADP (green) complex. The SOCS1 kinase inhibitory region (KIR), the extended SH2 subdomain (ESS) as well as the SH2 domain proper (but not its phosphotyrosine-binding groove) all make substantial contacts with the C-lobe of the JAK1 kinase domain. Notably, JAK1 Tyr 1034 and 1035 in the activation loop are unphosphorylated in this structure. b Details of key SOCS1 interactions centred around the JAK1 GQM motif (electrostatic surface view). c JAK1 from the JAK1/SOCS1/ADP complex structure (beige) is shown overlaid with a JAK1/ADP structure (white, PDB: 5KHW). Small perturbations in the JAK1 activation loop and GQM motif can be seen between the two structures as well as a larger perturbation in the glycine-rich loop. The JAK1 activation loop is seen in the active conformation both in the presence and absence of SOCS1, despite being unphosphorylated in the SOCS1 bound structure. d Ribbon diagram of the structure of SOCS1 in the presence (red) and absence (white) of JAK1. The major conformational change to SOCS1 upon JAK1 binding is an ordering of the kinase inhibitory region. e The SOCS1 KIR is shown overlaid with the SOCS3 KIR (green) (PDB ID: 4GL9). Residue numbering of SOCS1 orthologues in all figures refers to the analogous residue in the human sequence
Fig. 2 The structure of a SOCS1/JAK1/ADP complex. a Cartoon representation of the JAK1 (beige) /SOCS1 (red) /ADP (green) complex. The SOCS1 kinase inhibitory region (KIR), the extended SH2 subdomain (ESS) as well as the SH2 domain proper (but not its phosphotyrosine-binding groove) all make substantial contacts with the C-lobe of the JAK1 kinase domain. Notably, JAK1 Tyr 1034 and 1035 in the activation loop are unphosphorylated in this structure. b Details of key SOCS1 interactions centred around the JAK1 GQM motif (electrostatic surface view). c JAK1 from the JAK1/SOCS1/ADP complex structure (beige) is shown overlaid with a JAK1/ADP structure (white, PDB: 5KHW). Small perturbations in the JAK1 activation loop and GQM motif can be seen between the two structures as well as a larger perturbation in the glycine-rich loop. The JAK1 activation loop is seen in the active conformation both in the presence and absence of SOCS1, despite being unphosphorylated in the SOCS1 bound structure. d Ribbon diagram of the structure of SOCS1 in the presence (red) and absence (white) of JAK1. The major conformational change to SOCS1 upon JAK1 binding is an ordering of the kinase inhibitory region. e The SOCS1 KIR is shown overlaid with the SOCS3 KIR (green) (PDB ID: 4GL9). Residue numbering of SOCS1 orthologues in all figures refers to the analogous residue in the human sequenceCC BY · PubMed Central
Fig. 3 The kinase inhibitory region acts as a pseudosubstrate. a Molecular details of the interaction between the SOCS1 kinase inhibitory region (red) and JAK1 (beige). The interaction is driven by six continuous residues in the SOCS1 KIR (His54 to Arg59), these primarily interact with the activation loop, GQM motif and glycine-rich loop of JAK1. Black dashed lines indicate hydrogen-bonds whilst grey dotted lines are van der Waals contacts. b A model of a peptide substrate (green) bound to the JAK1 kinase domain (based on the insulin receptor kinase/substrate structure (PDB: 1IRK)) indicates that the SOCS1 KIR acts as a pseudosubstrate with His54 mimicking the substrate tyrosine. c The GQM motif (Gly1097, Gln1098, Met1099) in JAK1 is a primary interaction site with SOCS1 and contacts the KIR, extended SH2 subdomain and SH2 domain (particularly the BC loop). d IC50 values of SOCS1 KIR mutants indicate that each residue of the KIR contributes to the affinity of the interaction. Errors are standard error of the mean from two independent experiments. e Sequence alignment of the KIR of SOCS1 from various species shows a high level of sequence conservation
Fig. 3 The kinase inhibitory region acts as a pseudosubstrate. a Molecular details of the interaction between the SOCS1 kinase inhibitory region (red) and JAK1 (beige). The interaction is driven by six continuous residues in the SOCS1 KIR (His54 to Arg59), these primarily interact with the activation loop, GQM motif and glycine-rich loop of JAK1. Black dashed lines indicate hydrogen-bonds whilst grey dotted lines are van der Waals contacts. b A model of a peptide substrate (green) bound to the JAK1 kinase domain (based on the insulin receptor kinase/substrate structure (PDB: 1IRK)) indicates that the SOCS1 KIR acts as a pseudosubstrate with His54 mimicking the substrate tyrosine. c The GQM motif (Gly1097, Gln1098, Met1099) in JAK1 is a primary interaction site with SOCS1 and contacts the KIR, extended SH2 subdomain and SH2 domain (particularly the BC loop). d IC50 values of SOCS1 KIR mutants indicate that each residue of the KIR contributes to the affinity of the interaction. Errors are standard error of the mean from two independent experiments. e Sequence alignment of the KIR of SOCS1 from various species shows a high level of sequence conservationCC BY · PubMed Central
Fig. 4 Structure of the SOCS1–Elongin B/C complex. a Structure of Xenopus laevis SOCS1 (red) in complex with Elongin B (pale green) and Elongin C (green). b The SOCS1 SOCS Box is shown overlaid with the structure of SOCS2 (cyan) bound to Cullin5 (blue). SOCS1 Asn197 takes the place of terminal proline typically seen in the canonical Cullin5 binding motif (LPφP). This asparagine clashes with Trp53 of Cullin5. Likewise, the Arg186 (SOCS2)-Thr117 (Cul5) hydrogen bond is lost in SOCS1 which has a valine (Val200) in place of the arginine. c Model of the JAK1-SOCS1-Elongin B/C-Cullin5-Rbx2 (white) complex based upon the SOCS1/JAK1 (this manuscript), SOCS2/ElonginB/ElonginC/Cullin5 NTD (PDB: 4JGH) and Cul5 CTD/Rbx2 structures (PDB: 3DPL). The SOCS1/JAK1 interaction orients JAK1 toward rbx2, which is the site of activated-ubiquitin (ubiquitin-E2) binding
Fig. 4 Structure of the SOCS1–Elongin B/C complex. a Structure of Xenopus laevis SOCS1 (red) in complex with Elongin B (pale green) and Elongin C (green). b The SOCS1 SOCS Box is shown overlaid with the structure of SOCS2 (cyan) bound to Cullin5 (blue). SOCS1 Asn197 takes the place of terminal proline typically seen in the canonical Cullin5 binding motif (LPφP). This asparagine clashes with Trp53 of Cullin5. Likewise, the Arg186 (SOCS2)-Thr117 (Cul5) hydrogen bond is lost in SOCS1 which has a valine (Val200) in place of the arginine. c Model of the JAK1-SOCS1-Elongin B/C-Cullin5-Rbx2 (white) complex based upon the SOCS1/JAK1 (this manuscript), SOCS2/ElonginB/ElonginC/Cullin5 NTD (PDB: 4JGH) and Cul5 CTD/Rbx2 structures (PDB: 3DPL). The SOCS1/JAK1 interaction orients JAK1 toward rbx2, which is the site of activated-ubiquitin (ubiquitin-E2) bindingCC BY · PubMed Central
Fig. 5 SOCS1 does not bind to any pTyr sites on the interferon gamma receptor. a Schematic diagrams of the IFN-α, ɣ and IL-2 receptors. All intracellular tyrosines are shown. b Table showing the binding affinities of human SOCS1 for each IFN-ɣ and IL-2 receptor phosphopeptide. Errors represent standard deviation from three independent experiments. c Representative ITC curves are shown for the four IL-2R phosphopeptides that bind to SOCS1 with sub-micromolar affinity
Fig. 5 SOCS1 does not bind to any pTyr sites on the interferon gamma receptor. a Schematic diagrams of the IFN-α, ɣ and IL-2 receptors. All intracellular tyrosines are shown. b Table showing the binding affinities of human SOCS1 for each IFN-ɣ and IL-2 receptor phosphopeptide. Errors represent standard deviation from three independent experiments. c Representative ITC curves are shown for the four IL-2R phosphopeptides that bind to SOCS1 with sub-micromolar affinityCC BY · PubMed Central
Fig. 6 SOCS1 binds to the activation loop peptides from all four JAKs. a Table showing the affinity and enthalpy of each SOCS1/JAK activation loop peptide interaction as determined by isothermal titration calorimetry. Human SOCS1 binds to phosphorylated peptides representing all four JAK activation loops. The first phosphotyrosine of the JAK1 activation loop (pTyr1034) is the key residue for SOCS1 binding. Errors represent standard error of the mean from three independent experiments. b Representative ITC binding data for the four JAK activation loop peptides (doubly-phosphorylated) binding to SOCS1 used to generate a. c NMR analysis of phosphopeptide binding. 1H–15N SOFAST HMQC spectra of ggSOCS1 in the presence (blue) and absence (black) of the JAK1 activation loop are shown overlaid. Both spectra were assigned, the labels indicate the positions of amide resonances from the bound form of the protein. d NMR analysis of JAK binding in the presence of exogenous phosphopeptide. 1H–15N SOFAST HMQC spectra of ggSOCS1/activation loop complex in the presence (red) and absence (blue) of the JAK1 kinase domain are shown overlaid. The sidechain epsilon NH resonance of Arg127 from both JAK-bound and unbound forms are indicated. These are of opposite phase to backbone amide resonances. The presence of the Arg127 resonance in that section of spectra indicates that the phosphopeptide-binding groove is occupied in both complexes. e NMR analysis of JAK binding in the absence of exogenous phosphopeptide. 1H–15N SOFAST HMQC spectra of ggSOCS1 in the presence (green) and absence (black) of the JAK1 kinase domain are shown overlaid. The line-broadening in the green spectra indicated the formation of a SOCS1/JAK complex and the lack of the Arg127 sidechain resonance in either spectra indicates the phosphotyrosine-binding groove is unoccupied
Fig. 6 SOCS1 binds to the activation loop peptides from all four JAKs. a Table showing the affinity and enthalpy of each SOCS1/JAK activation loop peptide interaction as determined by isothermal titration calorimetry. Human SOCS1 binds to phosphorylated peptides representing all four JAK activation loops. The first phosphotyrosine of the JAK1 activation loop (pTyr1034) is the key residue for SOCS1 binding. Errors represent standard error of the mean from three independent experiments. b Representative ITC binding data for the four JAK activation loop peptides (doubly-phosphorylated) binding to SOCS1 used to generate a. c NMR analysis of phosphopeptide binding. 1H–15N SOFAST HMQC spectra of ggSOCS1 in the presence (blue) and absence (black) of the JAK1 activation loop are shown overlaid. Both spectra were assigned, the labels indicate the positions of amide resonances from the bound form of the protein. d NMR analysis of JAK binding in the presence of exogenous phosphopeptide. 1H–15N SOFAST HMQC spectra of ggSOCS1/activation loop complex in the presence (red) and absence (blue) of the JAK1 kinase domain are shown overlaid. The sidechain epsilon NH resonance of Arg127 from both JAK-bound and unbound forms are indicated. These are of opposite phase to backbone amide resonances. The presence of the Arg127 resonance in that section of spectra indicates that the phosphopeptide-binding groove is occupied in both complexes. e NMR analysis of JAK binding in the absence of exogenous phosphopeptide. 1H–15N SOFAST HMQC spectra of ggSOCS1 in the presence (green) and absence (black) of the JAK1 kinase domain are shown overlaid. The line-broadening in the green spectra indicated the formation of a SOCS1/JAK complex and the lack of the Arg127 sidechain resonance in either spectra indicates the phosphotyrosine-binding groove is unoccupiedCC BY · PubMed Central
Fig. 7 Steric hindrance prevents SOCS1 from binding the JAK activation loop in the intact kinase domain. a ITC binding data indicates both human SOCS1ΔKIR B/C (left) and ggSOCS1ΔKIR B/C (right) do not bind to the JAK2 kinase domain but do bind to JAK2 activation loop peptides. b Size exclusion chromatography (using a Superdex 200 10/300 column) data indicate that SOCS1ΔKIR B/C does not form a complex with JAK2. As positive controls, wild-type SOCS1 B/C does form a complex with JAK2, while SOCS1ΔKIR B/C does form a complex with JAK1 when the activation loop peptide (ALP) motif is artificially fused to the N-terminus of JAK. (ALP-JAK1KD). c Kinase inhibition assays show that SOCS1 inhibits JAK2 with similar IC50 values in the absence and presence of activation loop peptide. Conversely, SOCS1 displays a lower IC50 against ALP-JAK1KD. Error bars represent the range of the data from two technical replicates. d NMR data indicate that ggSOCS1ΔKIRΔSOCSbox does not bind the phosphorylated JAK2 kinase domain. 1H–15N SOFAST HMQC spectra of 15N-labelled ggSOCS1ΔKIRΔSOCSbox in the presence (red) and absence (black) of the phosphorylated JAK2 kinase domain (unlabelled) are shown overlaid. e Size exclusion chromatography data (using a Superdex 75 10/30 column) indicate that SOCS1ΔKIR B/C forms a complex with JAK2 in the presence of 5 µM CHZ-868 Type II inhibitor, but not in its absence. f Schematic summary of SOCS1 SH2 domain interactions. Under normal conditions, SOCS1ΔKIR does not bind to the JAK activation loop due to steric hinderance. In the presence of a Type II inhibitor, the SOCS1 SH2 domain weakly associates with the JAK activation loop
Fig. 7 Steric hindrance prevents SOCS1 from binding the JAK activation loop in the intact kinase domain. a ITC binding data indicates both human SOCS1ΔKIR B/C (left) and ggSOCS1ΔKIR B/C (right) do not bind to the JAK2 kinase domain but do bind to JAK2 activation loop peptides. b Size exclusion chromatography (using a Superdex 200 10/300 column) data indicate that SOCS1ΔKIR B/C does not form a complex with JAK2. As positive controls, wild-type SOCS1 B/C does form a complex with JAK2, while SOCS1ΔKIR B/C does form a complex with JAK1 when the activation loop peptide (ALP) motif is artificially fused to the N-terminus of JAK. (ALP-JAK1KD). c Kinase inhibition assays show that SOCS1 inhibits JAK2 with similar IC50 values in the absence and presence of activation loop peptide. Conversely, SOCS1 displays a lower IC50 against ALP-JAK1KD. Error bars represent the range of the data from two technical replicates. d NMR data indicate that ggSOCS1ΔKIRΔSOCSbox does not bind the phosphorylated JAK2 kinase domain. 1H–15N SOFAST HMQC spectra of 15N-labelled ggSOCS1ΔKIRΔSOCSbox in the presence (red) and absence (black) of the phosphorylated JAK2 kinase domain (unlabelled) are shown overlaid. e Size exclusion chromatography data (using a Superdex 75 10/30 column) indicate that SOCS1ΔKIR B/C forms a complex with JAK2 in the presence of 5 µM CHZ-868 Type II inhibitor, but not in its absence. f Schematic summary of SOCS1 SH2 domain interactions. Under normal conditions, SOCS1ΔKIR does not bind to the JAK activation loop due to steric hinderance. In the presence of a Type II inhibitor, the SOCS1 SH2 domain weakly associates with the JAK activation loopCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 456

Metadata

Authors
Liau, N. P. D., Laktyushin, A., Lucet, I. S., Murphy, J. M., Yao, S., Whitlock, E., Callaghan, K., Nicola, N. A., Kershaw, N. J., & Babon, J. J.
Affiliations
The University of Melbourne (AU)
Corresponding author
  • Kershaw, Nadia J.
  • Babon, Jeffrey J.
Venue
Nature Communications
Published
2018-04-19
Volume
9
Issue
1
Pages
1558-1558
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2801285271
Cited by
456
References
59
Citations by year
2026: 47 · 2025: 70 · 2024: 64 · 2023: 77 · 2022: 65 · 2021: 61 · 2020: 46 · 2019: 18 · 2018: 8
FWCI
12.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Commonwealth Scientific and Industrial Research Organisation
  • Australian Synchrotron
  • Medical Research Council
  • National Health and Medical Research Council (1113577, 1122999, 9000220)
  • Cancer Council Victoria (1065180)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Keywords
SOCS1, JAK/STAT signaling, negative feedback regulation, ubiquitination, interferon-gamma signaling, cytokine signaling, SOCS3, protein structure
MeSH terms
Suppressor of Cytokine Signaling 1 Protein, Suppressor of Cytokine Signaling 3 Protein, Protein Domains, Janus Kinase Inhibitors, Binding Sites, Humans, Interferon-gamma, Models, Molecular, Phosphorylation, Signal Transduction, Crystallography, X-Ray, Cullin Proteins, STAT Transcription Factors, Janus Kinase 1, Janus Kinase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The molecular basis of JAK/STAT inhibition by SOCS1. https://app.cochat.ai/papers/10.1038/s41467-018-04013-1
The paper
Liau, N. P. D., Laktyushin, A., Lucet, I. S., Murphy, J. M., Yao, S., Whitlock, E., Callaghan, K., Nicola, N. A., Kershaw, N. J., & Babon, J. J. (2018). The molecular basis of JAK/STAT inhibition by SOCS1. Nature Communications. https://doi.org/10.1038/s41467-018-04013-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.